Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders
Brian T. Montague,Matthew F. Wipperman,Erica Chio,Rowena Crow,Andrea T. Hooper,Meagan P. O'Brien,Eric A. F. Simões +6 more
Reads0
Chats0
TLDR
In this article , the authors evaluated the serum anti-spike (anti-S) IgG, anti-nucleocapsid (antiN) and anti-S IgA response following vaccination against SARS-CoV-2 in a cohort of first-responders.Abstract:
Abstract IgA plays an important early neutralizing role after SARS-CoV-2 infection. Systemically administered vaccines typically produce an IgM/IgG predominant response. We evaluated the serum anti-spike (anti-S) IgG, anti-nucleocapsid (anti-N) IgG and anti-S IgA response following vaccination against SARS-CoV-2 in a cohort of first-responders. Among the 378 completely vaccinated participants, 98% were positive for anti-S IgG and 96% were positive for anti-S IgA. Nine percent were positive for anti-N IgG suggesting prior exposure to SARS-CoV-2. No statistically significant difference was seen in IgA response based on prior evidence infection (p = 0.18). Ninety-eight of those receiving the Moderna vaccine (98%) were positive for anti-S IgA as compared to 91% of those who received the Pfizer vaccine (p = 0.0009). The high proportion of participants observed to have a positive anti-S IgA response after vaccination suggests that the vaccines elicit a systemic response characterized by elevated levels of both IgG and IgA. read more
Citations
More filters
Journal ArticleDOI
Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens
Sitthichai Kanokudom,Nungruthai Suntronwong,Ritthideach Yorsaeng,Suvichada Assawakosri,Thanunrat Thongmee,Yong Poovorawan +5 more
TL;DR: In this article , the level of anti-S1 IgA in the serum of participants immunized with different COVID-19 vaccination regimens was evaluated and it was shown that heterologous boosters, especially after priming with an inactivated vaccine, elicited higher IgA levels than homologous booster.
Journal ArticleDOI
Significance of Anti-COVID-IgA antibody response in COVID-19 breakthrough infection in vaccinated patients - a single-centered study from Pakistan.
Journal ArticleDOI
Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination
Domenico Lo Tartaro,Anna Paolini,Marco Mattioli,Julian Swatler,Anita Neroni,Rebecca Borella,Elena Santacroce,Alessia Di Nella,Licia Gozzi,Stefano Busani,M C Cuccorese,Tommaso Trenti,Marianna Meschiari,Giovanni Guaraldi,Massimo Girardis,Cristina Mussini,Katarzyna Piwocka,Lara Gibellini,Andrea Cossarizza,Sara De Biasi +19 more
TL;DR: In this article , the authors investigated the magnitude, phenotype, and functionality of SARS-CoV-2-specific immune memory in two groups of healthy subjects after heterologous vaccination compared to a group of subjects who recovered from severe acute respiratory syndrome coronavirus 2 infection or vaccination.
References
More filters
Journal ArticleDOI
IgA dominates the early neutralizing antibody response to SARS-CoV-2.
Delphine Sterlin,Delphine Sterlin,Alexis Mathian,Makoto Miyara,Audrey Mohr,François Anna,Laetitia Claër,Paul Quentric,Jehane Fadlallah,Hervé Devilliers,Pascale Ghillani,Cary Gunn,Rick Hockett,Sasi Mudumba,Amélie Guihot,Charles Edouard Luyt,Julien Mayaux,Alexandra Beurton,Salma Fourati,Timothée Bruel,Olivier Schwartz,Jean Marc Lacorte,Hans Yssel,Christophe Parizot,Karim Dorgham,Pierre Charneau,Zahir Amoura,Guy Gorochov +27 more
TL;DR: Specific IgA serum concentrations decreased notably 1 month after the onset of symptoms, but neutralizing IgA remained detectable in saliva for a longer time (days 49 to 73 post-symptoms).
Journal ArticleDOI
Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines
TL;DR: An update of the current status on influenza vaccination is provided and concentrates on the two main types of influenza vaccines currently in use, namely the cold‐adapted vaccine (CAV) given intranasally/orally, and the inactivated vaccine (IV) delivered subcutanously or intramuscularly.
Journal ArticleDOI
Enhanced SARS-CoV-2 neutralization by dimeric IgA.
Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Charlotte Viant,Christian Gaebler,Melissa Cipolla,Hans-Heinrich Hoffmann,Thiago Y. Oliveira,Deena A. Oren,Victor A. Ramos,Lilian Nogueira,Eleftherios Michailidis,Davide F. Robbiani,Anna Gazumyan,Charles M. Rice,Theodora Hatziioannou,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +21 more
TL;DR: The authors found that dimeric IgA antibodies neutralized SARS-CoV-2 more effectively than their monomeric counterparts, and suggested that vaccines that induce dimeric igA antibodies at mucosal surfaces may be good candidates for protection against SARS, the virus that causes COVID-19.
Journal ArticleDOI
Structure and function relationships in IgA
Jenny M. Woof,Michael W. Russell +1 more
TL;DR: An overview of human IgA structure is provided, describing the distinguishing features of the IgA1 and IgA2 subclasses and mapping the sites of interaction with host receptors important for IgA's functional repertoire.
Journal ArticleDOI
Lung mucosal immunity: immunoglobulin‐A revisited
TL;DR: The role of IgA in the defence of mucosal surfaces has now expanded from a limited role of scavenger of exogenous material to a broader protective function with potential applications in immunotherapy.